Aktualnie w Polsce są 53 badania kliniczne w obszarze: guzy lite (51 rekrutuje, 2 wkrótce zaczną rekrutację). Badania prowadzą ośrodki w 30 miastach, m.in. Warszawa, Gdańsk, Kraków, Poznań.
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
+14PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer
PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
+15REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
+10A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
+4Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
+27Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
+2A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid…
+14Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
+11A Phase 1/2 Trial of TER-2013 in Patients with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
+2Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
+20Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
RVU120 Rollover Study
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
+2Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically…
+11A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
+4A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
+15Phase 1/2 Study of PYX-201 in Combination with Pembrolizumab in Advanced Solid Tumors
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
+9An open-label, multicentre, rollover study to evaluate safety and antineoplastic activity of OATD-02 in patients with selected advances and/or metastatic solid tumours who…
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
+10AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
+7Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
Według daty pojawienia się badania w rejestrze (CTIS lub ClinicalTrials.gov).
Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań w obszarze: guzy lite możesz się kwalifikować.
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 2 października 2026.